Astellas Pharma Inc (ALPMY)

16.04
+0.11(+0.69%)
  • Volume:
    41,956
  • Bid/Ask
    0.00/0.00
  • Day's Range
    15.95 - 16.15

ALPMY Overview

Prev. Close
16.04
Day's Range
15.95 - 16.15
Revenue
0
Open
16.05
52 wk Range
12.48 - 18.43
EPS
0
Volume
41,956
Market Cap
30.33B
Dividend (Yield)
N/A (N/A)
Average Volume (3m)
92,905
P/E Ratio
N/A
Beta
0
1-Year Change
2.82%
Shares Outstanding
0
Next Earnings Date
13 May 2021
What is your sentiment on Astellas Pharma Inc?
or
Market is currently closed. Voting is open during market hours.

Astellas Pharma Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellSellSellStrong Buy
Technical IndicatorsSellStrong BuyBuyStrong SellBuy
SummaryStrong SellNeutralNeutralStrong SellStrong Buy

Astellas Pharma Inc Company Profile

Astellas Pharma Inc Company Profile

Industry
Major Drugs
Employees
15883
Market
Japan

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.